In medical imaging, such as X-rays, MRI, CT, and ultrasound, contrast media or contrast agent is used to improve the image of a body part. To temporarily alter the way in which imaging devices or x-rays interact with the body, these substances are often used. As a result of the enhanced visibility of blood vessels, tissues, and organs, doctors are better able to make accurate diagnoses. In order to better differentiate structures or tissues of interest from the surrounding tissue, these substances are injected into the body prior to an imaging scan. Contrast media or contrast agent can be injected into a blood vessel, swallowed, sprayed into the urethra, or given via enema (rectally).
Request Sample Report + All Related Graphs & Charts:
https://www.coherentmarketinsights.com/insight/request-sample/1210
We have an updated report [Version – 2023] available.
(The sample of this report is readily available on request. The report sample contains a brief introduction to the research report, a Table of Contents, a Graphical introduction of regional analysis, Top players in the market with their revenue analysis, and our research methodology.)
The development of gas micro bubbles for use in MRI imaging is anticipated to fuel the expansion of the contrast media/contrast agent market
The increasing prevalence of chronic diseases like cardiovascular disease, gastrointestinal disorders, and cancer, as well as the use of cutting-edge technologies like gas micro bubble technology in MRI imaging, are the primary forces propelling the development of contrast Media/contrast agent. The development of better medical imaging tools and the rising need for image-guided procedures and diagnostics are driving the expansion of this market. By 2030, the number of new cases of cancer is projected to rise to 21.7 Mn, and the number of deaths from cancer is projected to rise to 13 Mn, all according to the International Agency for Research on Cancer (IARC). However, factors such as the high cost of contrast media injectors and adverse effects of contrast agents, such as kidney disease, are limiting the market’s expansion.
The expansion of the contrast media market is predicted to be fueled by the approval and introduction of novel agents with a favorable safety profile. In 2016, the Food and Drug Administration (FDA) authorized the use of Gadavist (gadobutrol) injection, made by Bayer AG, in conjunction with MRA to assess the presence of renal artery disease in both adults and children. Furthermore, the FDA approved GE Healthcare’s Visipaque (iodixanol) for diagnostic evaluation of patients aged 12 and up with suspected coronary artery disease via coronary computed tomography angiography (CCTA) in May 2017.
The contrast media/contrast agent market is anticipated to grow as a result of product launches and inorganic growth strategies such as acquisition and collaboration among market players
The expansion of the market for contrast media/contrast agent is anticipated to be driven by the concentration of key players on product approvals and launches. For example, Bayer HealthCare introduced the Medrad Stellant Flex CT injection system in September 2019 so that they could provide patients with a system that is driven by the user, as well as patient-specific protocols and individualized imaging. Similarly, Bracco Diagnostics Inc., a division of Bracco Imaging S.p.A., released an adaptable and interactive media kit in July 2019 with the goal of improving the brand’s standing with users and attracting more doctors to recommend the service. The press release, patient brochure, and letter and referrers brochure in the media kit are all editable.
In the first contrast agent for cardiac MR imaging in patients suspected of suffering from coronary artery disease, Bayer HealthCare’s Gadavist (gadobutrol) injection was approved by the U.S. Food and Drug Administration in July 2019.
Clariscan, a gadolinium-based contrast agent developed by GE Healthcare and released in March 2017, helps radiologists better see anomalies in the brain, spine, and other tissues.
An additional factor that is expected to contribute significantly to market expansion is the growing popularity of merger and acquisition strategies among market participants. Such an example is the December 2014 announcement of a partnership between nanoPET Pharma GmbH and Boehringer Ingelheim Corporation. The partnership allowed nanoPET to take the lead in developing contrast agents for use in basic and pre-clinical research.
Detailed Segmentation :
Based on the media type:
- Microbubble Contrast Media
- Barium-Based Contrast Media
- Gadolinium-Based Contrast Media
- Iodinated Contrast Media
Based on the route of administration:
- Oral
- Intravenous
- Rectal
- Urethral
Based on the indication:
- Neurological Disorders
- Cardiovascular Disorders
- Nephrological Disorders
- Gastrointestinal Disorders
- Musculoskeletal Disorders
- Oncology
We Offer Customized Report, Click:
https://www.coherentmarketinsights.com/insight/request-customization/1210
Rising rates of cancer and heart disease are expected to make North America the most lucrative region for the contrast media/contrast agent industry
The market for contrast media/agent is dominated by North America, with Europe following close behind. Market growth in the contrast media/contrast agent in North America can be attributed to a number of factors, including: improved MRI techniques for the diagnosis of cardiovascular diseases; an increase in the occurrence of cancer and cardiac disorders; improvements in diagnostic technology; and the rise in the occurrence of image-guided surgical procedures. In 2016, there were an estimated 1,685,210 new cases of cancer in the United States, as reported by the National Cancer Institute. The CDC also reports that in 2017, approximately 28.4 Mn new cases of heart disease were identified in the United States.
Contrast media/agent market leaders include companies like Lantheus Medical Imaging, GE Healthcare, Bayer HealthCare, Bracco Imaging S.p.A., NanoPET Pharma GmbH, Guerbet Group, CMC Contrast AB, Daiichi Sankyo, and Subhra Pharma Private Limited.
Purchasing the Contrast Media/Contrast Agent Market:
➣ Outlook for the worldwide Contrast Media/Contrast Agent market in both developed and emerging markets, both now and in the future.
➣ Both the market segment with the largest projected share and the market segment with the highest CAGR throughout the projection period.
➣ Countries and regions anticipated to experience the fastest development throughout the projected period.
➣ The most recent innovations, market shares, and business tactics used by the key market participants.
➣ Study examines emerging market trends as well as the likelihood that various trends will impact expansion.
➣ Analysis also discusses the factors, challenges, and opportunities that will have a significant impact on the global Contrast Media/Contrast Agent industry.
➣ Research includes a detailed analysis of market statistics as well as historical and current growth conditions in order to provide futuristic growth estimates.
Purchase This Complete Business Report:
https://www.coherentmarketinsights.com/insight/buy-now/1210
Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Contrast Media/Contrast Agent Market Size Analysis from 2023 to 2030
11.6 COVID-19 Outbreak: Contrast Media/Contrast Agent Industry Impact
Chapter 2 Global Contrast Media/Contrast Agent Competition by Types, Applications, and Top Regions and Countries
2.1 Global Contrast Media/Contrast Agent (Volume and Value) by Type
2.3 Global Contrast Media/Contrast Agent (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Contrast Media/Contrast Agent Sales, Consumption, Export, Import by Regions (2017-2023)
Chapter 5 North America Contrast Media/Contrast Agent Market Analysis
Chapter 6 East Asia Contrast Media/Contrast Agent Market Analysis
Chapter 7 Europe Contrast Media/Contrast Agent Market Analysis
Chapter 8 South Asia Contrast Media/Contrast Agent Market Analysis
Chapter 9 Southeast Asia Contrast Media/Contrast Agent Market Analysis
Chapter 10 Middle East Contrast Media/Contrast Agent Market Analysis
Chapter 11 Africa Contrast Media/Contrast Agent Market Analysis
Chapter 12 Oceania Contrast Media/Contrast Agent Market Analysis
Chapter 13 South America Contrast Media/Contrast Agent Market Analysis
Chapter 14 Company Profiles and Key Figures in Contrast Media/Contrast Agent Business
Chapter 15 Global Contrast Media/Contrast Agent Market Forecast (2023-2030)
Chapter 16 Conclusions
Explore More Related Insights:
Medical Imaging Reagents Market
Diagnostic Radiopharmaceuticals And Contrast Media Market
Contrast Media Injectors Market
Life Science Microscopy Devices Market
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Mr. Shah
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400, Burlingame
CA 94010, United States
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
JAPAN: +81-50-5539-1737
INDIA: +91-848-285-0837